NASDAQ:GRFS - Grifols Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: -10.79 %
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$12.33
▼ -0.2 (-1.60%)

This chart shows the closing price for GRFS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Grifols Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRFS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRFS

Analyst Price Target is $11.00
▼ -10.79% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Grifols in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a -10.79% upside from the last price of $12.33.

This chart shows the closing price for GRFS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Grifols. This rating has held steady since December 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/31/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/27/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/27/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/24/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/23/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/4/2022JPMorgan Chase & Co.Lower Price Target€15.00 ➝ €11.00Low
11/4/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldMedium
10/19/2021BarclaysDowngradeOverweight ➝ UnderweightMedium
10/6/2021CitigroupUpgradeNeutral ➝ BuyHigh
8/4/2021Credit Suisse GroupReiterated RatingOutperformLow
8/4/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
6/28/2021BarclaysReiterated RatingOverweightLow
6/14/2021Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyMedium
4/27/2021Berenberg BankReiterated RatingBuyMedium
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageHoldLow
3/23/2021Credit Suisse GroupUpgradeNeutral ➝ OutperformHigh
3/11/2021HSBCUpgradeHold ➝ BuyHigh
3/10/2021Morgan StanleyReiterated RatingOverweightHigh
3/2/2021Credit Suisse GroupReiterated RatingNeutralLow
3/2/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
2/12/2021Berenberg BankReiterated RatingBuyLow
1/22/2021BarclaysReiterated RatingOverweightLow
1/20/2021Credit Suisse GroupReiterated RatingNeutralLow
1/13/2021Morgan StanleyReiterated RatingOverweightLow
12/9/2020Morgan StanleyReiterated RatingOverweightLow
11/6/2020Morgan StanleyReiterated RatingOverweightLow
10/30/2020Berenberg BankReiterated RatingBuyLow
10/1/2020CitigroupUpgradeSell ➝ NeutralLow
9/30/2020Morgan StanleyReiterated RatingOverweightLow
7/21/2020Berenberg BankReiterated RatingBuyLow
6/23/2020Morgan StanleyReiterated RatingOverweightLow
6/10/2020Berenberg BankReiterated RatingBuyMedium
6/9/2020CitigroupDowngradeNeutral ➝ SellMedium
6/9/2020HSBCUpgradeReduce ➝ HoldMedium
6/1/2020BarclaysReiterated RatingOverweightLow
4/21/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralMedium
3/27/2020Kepler Capital MarketsReiterated RatingHoldMedium
3/25/2020CitigroupDowngradeBuy ➝ NeutralLow
3/6/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
3/1/2020Kepler Capital MarketsReiterated RatingHoldHigh
12/12/2019William BlairReiterated RatingOutperformLow
12/9/2019Banco SabadellUpgradeSell ➝ BuyMedium
10/30/2019Berenberg BankUpgradeBuyLow
10/28/2019SantanderUpgradeHold ➝ BuyLow
6/27/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$21.00 ➝ $22.50High
2/8/2019Berenberg BankDowngradeBuy ➝ HoldHigh
1/2/2019Morgan StanleyLower Price TargetUnderweight ➝ Underweight$20.00 ➝ $19.00Low
10/30/2018SantanderUpgradeUnderperform ➝ HoldLow
10/11/2018Berenberg BankUpgradeHold ➝ BuyMedium
10/3/2018UBS GroupDowngradeNeutral ➝ SellHigh
10/1/2018Morgan StanleyLower Price TargetUnderweight ➝ Underweight$22.00 ➝ $20.00Low
6/13/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
6/1/2018BarclaysInitiated CoverageOverweightMedium
3/14/2018HSBCUpgradeReduce ➝ HoldLow
3/1/2018Morgan StanleyLower Price TargetUnderweight ➝ Underweight$23.00 ➝ $22.00Medium
11/24/2017UBS GroupDowngradeOutperform ➝ Market PerformN/A
10/31/2017CitigroupInitiated CoverageBuy ➝ BuyN/A
7/4/2017Bank of AmericaReiterated RatingBuyMedium
6/30/2017The Goldman Sachs GroupDowngradeBuy ➝ NeutralLow
4/6/2017Bank of AmericaInitiated CoverageBuy ➝ BuyLow
3/30/2017JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightHigh
2/27/2017The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyN/A
(Data available from 1/22/2017 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/26/2021
  • 2 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/25/2021
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/24/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/24/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2021
  • 1 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2021
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2022

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Grifols logo
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
Read More

Today's Range

Now: $12.33
Low: $12.09
High: $12.52

50 Day Range

MA: $11.37
Low: $10.21
High: $12.63

52 Week Range

Now: $12.33
Low: $10.10
High: $19.34

Volume

1,129,879 shs

Average Volume

917,049 shs

Market Capitalization

$8.37 billion

P/E Ratio

10.82

Dividend Yield

5.75%

Beta

0.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Grifols?

The following Wall Street sell-side analysts have issued stock ratings on Grifols in the last twelve months: Barclays PLC, Berenberg Bank, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, HSBC Holdings plc, JPMorgan Chase & Co., Morgan Stanley, and Zacks Investment Research.
View the latest analyst ratings for GRFS.

What is the current price target for Grifols?

1 Wall Street analysts have set twelve-month price targets for Grifols in the last year. Their average twelve-month price target is $11.00, suggesting a possible downside of 10.8%. JPMorgan Chase & Co. has the highest price target set, predicting GRFS will reach $11.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $11.00 for Grifols in the next year.
View the latest price targets for GRFS.

What is the current consensus analyst rating for Grifols?

Grifols currently has 1 sell rating, 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GRFS will outperform the market and that investors should add to their positions of Grifols.
View the latest ratings for GRFS.

How do I contact Grifols' investor relations team?

Grifols' physical mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company's listed phone number is (493) 571-2200 and its investor relations email address is [email protected] The official website for Grifols is www.grifols.com.